Brief Reports
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 1, 2004; 10(11): 1659-1662
Published online Jun 1, 2004. doi: 10.3748/wjg.v10.i11.1659
Liver regional continuous chemotherapy: Use of femoral or subclavian artery for percutaneous implantation of catheter-port systems
An-Long Zhu, Lian-Xin Liu, Da-Xun Piao, Ya-Xin Lin, Jin-Peng Zhao, Hong-Chi Jiang
An-Long Zhu, Lian-Xin Liu, Da-Xun Piao, Jin-Peng Zhao, Hong-Chi Jiang, Department of General Surgery, First Clinical College, Harbin Medical University, Harbin, 150001, Heilongjiang Province, China
Ya-Xin Lin, Department of Neurology, Heilongjiang Province Hospital, Harbin 150036, Heilongjiang Province, China
Author contributions: All authors contributed equally to the work.
Supported by National Natural Science Foundation of China, No. 30300339
Correspondence to: Lian-Xin Liu, Department of General surgery, First Clinical College, Harbin Medical University, Harbin, 150001, Heilongjiang Province, China.
Telephone: +86-451-53658828 Fax: +86-451-53670428
Received: February 6, 2004
Revised: February 8, 2004
Accepted: February 18, 2004
Published online: June 1, 2004

AIM: To evaluate the feasibility and safety of the intraarterial chemotherapy of the liver cancer by an interventional method, catheter-port system.

METHODS: Thirty-two catheter-port systems were implanted percutaneously via the femoral artery or subclavian artery. Chemotherapies were performed 0-5 d after the implantation of the catheter-port systems. The mean interval between two sequent chemotherapies was 4 wk. The occurrence of side effects of the implantation was examined clinically.

RESULTS: Implantation of the catheter-port was successful in all patients. Mean patency period was 210 d. One occlusion (3.1%) of the catheter was observed. Displacement of the catheter was observed in one case (3.1%). One patient rated a hematoma in the chest wall as important. Mild hematoma was reported in 8 cases (25%). In 3 of 32 cases (9.4%), mild pain was reported initially, and dysesthesia was reported in seven (21.9%). No patient rated overall discomfort as mild, severe, or important.

CONCLUSION: Percutaneous placement is feasible and safe for liver regional continuous chemotherapy. Compared with surgical placement, the overall complication rate is comparable or less.

Keywords: $[Keywords]